1. Evaluating tocilizumab safety and immunomodulatory effects under ocular HTLV-1 infection in vitro.
- Author
-
Zhang J, Kamoi K, Zong Y, Yang M, Zou Y, and Ohno-Matsui K
- Subjects
- Humans, Cell Line, T-Lymphocytes immunology, T-Lymphocytes drug effects, Retinal Pigment Epithelium drug effects, Retinal Pigment Epithelium virology, Retinal Pigment Epithelium immunology, Coculture Techniques, Cell Survival drug effects, Viral Load drug effects, Human T-lymphotropic virus 1, HTLV-I Infections drug therapy, HTLV-I Infections immunology, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized pharmacology, Antibodies, Monoclonal, Humanized adverse effects
- Abstract
There is growing interest in evaluating the safety and therapeutic potential of existing treatments such as tocilizumab (TCZ), an IL-6 receptor antagonist used to treat inflammatory diseases. However, there have been reports of increased inflammation in patients with HTLV-1 uveitis after TCZ treatment, and its ocular safety in the HTLV-1 infected state remains unknown. This study focused on assessing the impact of TCZ on HTLV-1-infected ocular cells using an in vitro model in which retinal pigment epithelial cells were cocultured with irradiated HTLV-1-infected T-cell lines. TCZ did not significantly affect cellular viability, inflammatory markers, or HTLV-1 proviral loads at various concentrations (25/50/100 µg/ml), indicating no increased risk of HTLV-1 viral infection and no exacerbation of the inflammatory aspects of HTLV-1 infection in the ocular cells. These promising results support the potential of TCZ as a safe treatment option for HTLV-1-infected patients, particularly those with eye infections., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF